Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Treatment of Inflammation in the Renal Allograft
NCT02108600Phase 2Completed
- Start
- Jun 2014
- Primary completion
- Dec 2018
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in kidney transplant rejection. Started Jun 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02108600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108600.